References
- Bassett R M, Driebergen R. Continued improvements in the quality and consistency of follitropin alfa, recombinant human FSH. Reprod Biomed Online 2005; 10: 169–177
- Wolfenson C, Groisman J, Couto A S, Hedenfalk M, Cortvrindt R G, Smitz J E, Jespersen S. Batch-to-batch consistency of human-derived gonadotrophin preparations compared with recombinant preparations. Reprod Biomed Online 2005; 10: 442–454
- Filicori M, Fazleabas A T, Huhtaniemi I, Licht P, Rao Ch V, Tesarik J, Zygmunt M. Novel concepts of human chorionic gonadotropin: reproductive system interactions and potential in the management of infertility. Fertil Steril 2005; 84: 275–284
- Platteau P, Andersen A N, Balen A, Devroey P, Sørensen P, Helmgaard L, Arce J C. Menopur Ovulation Induction (MOI) Study Group Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study. Hum Reprod 2006; 21: 1798–1804
- Al-Inany H G, Abou-Setta A M, Aboulghar M A, Mansour R T, Serour G I. Efficacy and safety of human menopausal gonadotrophins versus recombinant FSH: a meta-analysis. Reprod Biomed Online 2008; 16: 81–88
- Coomarasamy A, Afnan M, Cheema D, van der Veen F, Bossuyt P M, van Wely M. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Hum Reprod 2008; 23: 310–315
- Platteau P, Smitz J, Albano C, Sørensen P, Arce J C, Devroey P. Exogenous luteinizing hormone activity may influence the treatment outcome in in vitro fertilization but not in intracytoplasmic sperm injection cycles. Fertil Steril 2004; 81: 1401–1414
- Higgins J PT, Thompson S G, Deeks J J, Altman D G. Measuring inconsistency in meta-analysis. BMJ 2003; 327: 557–560
- Gavaghan D J, Moore R A, McQuay H J. An evaluation of homogeneity tests in meta-analyses in pain using simulations of individual patient data. Pain 2000; 85: 415–424
- Andersen A N, Devroey P, Arce J C. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. Hum Reprod 2006; 21: 3217–3227
- Bosch E, Vidal C, Crespo J, Simon C, Remohi A, Pellicer A. Highly purified HMG versus rec-FSH in GnRH antagonist cycles. Hum Reprod 2005; 20(Suppl 1)i118
- European and Israeli Study Group on Highly Purified Menotropin versus Recombinant Follicle-Stimulating Hormone Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection cycles: a randomized, comparative trial. Fertil Steril 2002; 78: 520–528
- Hompes P G, Broekmans F J, Hoozemans D A, Schats R. FIRM Group. Effectiveness of highly purified human menopausal gonadotropin vs. recombinant follicle-stimulating hormone in first-cycle in vitro fertilization-intracytoplasmic sperm injection patients. Fertil Steril 2008; 89: 1685–1693
- Kilani Z, Dakkak A, Ghunaim S, Cognigni G E, Tabarelli C, Parmegiani L, Filicori M. A prospective, randomized, controlled trial comparing highly purified hMG with recombinant FSH in women undergoing ICSI: ovarian response and clinical outcomes. Hum Reprod 2003; 18: 1194–1199
- Strowitzki T. By treatment protocols: differences in treatment outcomes after antagonist downregulation. 5th World Congress on Ovulation Induction, RomeItaly, September, 13–15, 2007
- Zygmunt M, Herr F, Keller-Schoenwetter S, Kunzi-Rapp K, Münstedt K, Rao C V, Lang U, Preissner K T. Characterization of human chorionic gonadotropin as a novel angiogenic factor. J Clin Endocrinol Metab 2002; 87: 5290–5296
- Lévy D P, Navarro J M, Schattman G L, Davis O K, Rosenwaks Z. The role of LH in ovarian stimulation: exogenous LH: let's design the future. Hum Reprod 2000; 15: 2258–2265
- Kolibianakis E M, Zikopoulos K, Schiettecatte J, Smitz J, Tournaye H, Camus M, Van Steirteghem A C, Devroey P. Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF. Hum Reprod 2004; 19: 2490–2496
- Mansour R T, Aboulghar M A, Serour G I, Abbass A M. Co-culture of human pronucleate oocytes with their cumulus cells. Hum Reprod 1994; 9: 1727–1729
- Hassan H A. Cumulus cell contribution to cytoplasmic maturation and oocyte developmental competence in vitro. J Assist Reprod Genet 2001; 18: 539–543
- Taylor T H, Wright G, Jones-Colon S, Mitchell-Leef D, Kort H I, Nagy Z P. Comparison of ICSI and conventional IVF in patients with increased oocyte immaturity. Reprod Biomed Online 2008; 17: 46–52
- Parikh F R, Nadkarni S G, Naik N J, Naik D J, Uttamchandani S A. Cumulus coculture and cumulus-aided embryo transfer increases pregnancy rates in patients undergoing in vitro fertilization. Fertil Steril 2006; 86: 839–847
- Huang F J, Huang H W, Lan K C, Kung F T, Lin Y C, Chang H W, Chang S Y. The maturity of human cumulus-free oocytes is positively related to blastocyst development and viability. J Assist Reprod Genet 2002; 19: 555–560
- Van Wely M, Westergaard L G, Bossuyt P M, Van der Veen F. Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. Cochrane Database Syst Rev 2003; 1: CD003973
- Al-Inany H G, Abou-Setta A M, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev 2006; 3, CD001750